Ypsomed and smartpatient link connected injectors to MyTherapy
Ypsomed and smartpatient are teaming up to connect Ypsomed’s SmartPilot injection technology with the MyTherapy digital patient platform. The goal is to tie the injection moment to ongoing support between doses for people managing chronic conditions and to give pharma companies a reusable digital framework.
Why it matters: - The partnership aims to close a common gap in chronic disease care by linking the injection itself with ongoing digital support between doses. - Pharma companies could use one scalable system instead of building separate digital tools for each product. - The setup is designed to connect self-injection data with reminders, therapy education and adherence support across the full treatment journey.
What happened: - Ypsomed and smartpatient announced a collaboration to connect Ypsomed’s SmartPilot technology with MyTherapy. - The companies said the integration will combine connected self-injection with digital patient support for chronic therapies. - The first implementation is currently in development. - Further details will be shared as the collaboration progresses.
The details: - SmartPilot turns Ypsomed’s YpsoMate autoinjector into a connected medication delivery system. - The technology enables digital capture of injection-related information. - MyTherapy will place that information into a broader digital patient journey. - The combined offering is meant to link injection guidance, medication management, therapy education and continuous patient support. - The companies said pharma partners should be able to use the system without having to build a separate digital ecosystem for each product. - The model is intended to support tailored interventions based on relevant signals gathered over the course of treatment. - Ypsomed develops and manufactures self-injection systems for pharma and biotech companies worldwide. - smartpatient builds direct-to-patient solutions through MyTherapy across therapeutic areas and markets.
Between the lines: - The partnership reflects a broader shift in digital health from isolated point solutions to connected treatment journeys. - Ypsomed contributes expertise at the point of drug delivery, while smartpatient adds the continuous engagement layer. - A reusable platform could make connected therapies easier to deploy across multiple drugs and patient groups. - The companies are positioning the integration as an infrastructure play for pharma, not just a patient app feature.
What's next: - The companies will continue developing the first integrated version of SmartPilot and MyTherapy. - More information is expected later in the collaboration. - Pharma companies watching the rollout will be looking for proof that the system can scale across different therapies and markets.
The bottom line: - Ypsomed and smartpatient are building a connected-care model that extends digital support beyond the injection moment and into day-to-day therapy management.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Medical Industry Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.